KR20150028299A - 야누스 키나제 (ｊａｋ) 억제제 투여요법 - Google Patents

야누스 키나제 (ｊａｋ) 억제제 투여요법 Download PDF

Info

Publication number
KR20150028299A
KR20150028299A KR1020157001085A KR20157001085A KR20150028299A KR 20150028299 A KR20150028299 A KR 20150028299A KR 1020157001085 A KR1020157001085 A KR 1020157001085A KR 20157001085 A KR20157001085 A KR 20157001085A KR 20150028299 A KR20150028299 A KR 20150028299A
Authority
KR
South Korea
Prior art keywords
therapeutically effective
jak
effective dose
days
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157001085A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 제이. 곤잘레스
샐리 비. 코스그루브
필리스 비. 말파스
미카엘 롤프 스테게만
웬디 터너 콜라드
Original Assignee
조에티스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150028299(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 조에티스 엘엘씨 filed Critical 조에티스 엘엘씨
Publication of KR20150028299A publication Critical patent/KR20150028299A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020157001085A 2012-07-20 2013-07-18 야누스 키나제 (ｊａｋ) 억제제 투여요법 Ceased KR20150028299A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US61/674,289 2012-07-20
US201361815803P 2013-04-25 2013-04-25
US61/815,803 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007913A Division KR20170034949A (ko) 2012-07-20 2013-07-18 야누스 키나제 (ｊａｋ) 억제제 투여요법

Publications (1)

Publication Number Publication Date
KR20150028299A true KR20150028299A (ko) 2015-03-13

Family

ID=48901189

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157001085A Ceased KR20150028299A (ko) 2012-07-20 2013-07-18 야누스 키나제 (ｊａｋ) 억제제 투여요법
KR1020177007913A Ceased KR20170034949A (ko) 2012-07-20 2013-07-18 야누스 키나제 (ｊａｋ) 억제제 투여요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177007913A Ceased KR20170034949A (ko) 2012-07-20 2013-07-18 야누스 키나제 (ｊａｋ) 억제제 투여요법

Country Status (25)

Country Link
US (1) US9522151B2 (enExample)
EP (1) EP2874630B1 (enExample)
JP (2) JP6022063B2 (enExample)
KR (2) KR20150028299A (enExample)
CN (2) CN104470525A (enExample)
AU (1) AU2013292547B2 (enExample)
BR (1) BR112015000808A2 (enExample)
CA (1) CA2878867C (enExample)
CY (1) CY1121436T1 (enExample)
DK (1) DK2874630T3 (enExample)
ES (1) ES2707627T3 (enExample)
HK (2) HK1209314A1 (enExample)
HR (1) HRP20182088T1 (enExample)
HU (1) HUE042771T2 (enExample)
IN (1) IN2015DN00370A (enExample)
LT (1) LT2874630T (enExample)
MX (1) MX360857B (enExample)
NZ (1) NZ703152A (enExample)
PL (1) PL2874630T3 (enExample)
PT (1) PT2874630T (enExample)
RS (1) RS58242B1 (enExample)
SI (1) SI2874630T1 (enExample)
SM (1) SMT201900044T1 (enExample)
WO (1) WO2014015107A1 (enExample)
ZA (1) ZA201500134B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290421B1 (en) 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
WO2017143014A1 (en) * 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CN111499641B (zh) * 2019-01-30 2021-06-04 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4263559A1 (en) 2020-12-18 2023-10-25 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
MX2023010835A (es) * 2021-03-16 2023-09-29 Hk Inno N Corp Nuevas sales de compuestos heterocíclicos como inhibidores de proteínas quinasas y sus usos.
CA3216017A1 (en) * 2021-04-22 2022-10-27 Shengjian Huang Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
PT2384326E (pt) * 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina

Also Published As

Publication number Publication date
JP2017019816A (ja) 2017-01-26
HK1252083A1 (zh) 2019-05-17
HUE042771T2 (hu) 2019-07-29
CN108354938A (zh) 2018-08-03
AU2013292547B2 (en) 2017-05-04
CN104470525A (zh) 2015-03-25
RS58242B1 (sr) 2019-03-29
MX360857B (es) 2018-11-20
ZA201500134B (en) 2016-08-31
US9522151B2 (en) 2016-12-20
BR112015000808A2 (pt) 2017-06-27
EP2874630A1 (en) 2015-05-27
DK2874630T3 (en) 2019-01-28
JP2015522620A (ja) 2015-08-06
IN2015DN00370A (enExample) 2015-06-12
SI2874630T1 (sl) 2019-04-30
CA2878867C (en) 2018-01-09
ES2707627T3 (es) 2019-04-04
AU2013292547A1 (en) 2015-01-22
EP2874630B1 (en) 2018-12-05
CA2878867A1 (en) 2014-01-23
JP6022063B2 (ja) 2016-11-09
SMT201900044T1 (it) 2019-02-28
US20150126535A1 (en) 2015-05-07
PT2874630T (pt) 2019-01-31
HK1209314A1 (en) 2016-04-01
PL2874630T3 (pl) 2019-04-30
MX2015000871A (es) 2015-05-07
LT2874630T (lt) 2019-02-11
KR20170034949A (ko) 2017-03-29
HRP20182088T1 (hr) 2019-02-08
NZ703152A (en) 2016-03-31
CY1121436T1 (el) 2020-05-29
WO2014015107A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
KR20150028299A (ko) 야누스 키나제 (ｊａｋ) 억제제 투여요법
US20230138114A1 (en) Treatment of hand eczema
US20240390378A1 (en) Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
Urbanova et al. Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs
JP7640033B2 (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
KR20240009964A (ko) 결절성 양진 치료를 위한 jak1 경로 억제제
CN115038447A (zh) 用于治疗癌症的组合疗法
EP4282866A1 (en) Use of pyrido[1,2-a]pyrimidone analogue
US20230293544A1 (en) Methods, dosage regimens, and compositions for treating hidradenitis
TWI843217B (zh) 一種藥物組合及其應用
CN118984704A (zh) 治疗卵巢癌的药物组合和方法
CN102727477B (zh) 视黄酸及其衍生物在制备防治糖尿病药物中的应用

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20150115

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160519

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161108

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160519

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161108

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160718

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150115

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170220

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170206

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20161108

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160718

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160519

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150115

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170322

PJ0201 Trial against decision of rejection

Patent event date: 20170322

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170220

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20161108

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2017101001393

Request date: 20170322

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101001393; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170322

Effective date: 20180612

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20180612

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170322

Decision date: 20180612

Appeal identifier: 2017101001393